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Background: Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with an estimated prevalence of
about 1/3000, independent of ethnicity, race, or gender. Attention Deficit Hyperactivity like Disorder (ADHD)-like
characteristics are often reported in patients with NF1. We hypothesised that learning disabilities in NF1 children
were related to ADHD symptoms. Treatment with methylphenidate (MPD) has improved learning disabilities in
ADHD by acting on neurotransmitters. Our objective was to evaluate its efficacy on ADHD-like symptoms in
neurofibromatosis type 1 children (7–12 years).
Methods: This was a randomised, double blind, placebo controlled, and crossover trial comparing 0.5 to 0.8 mg/kg/d
of MPD as it is indicated for ADHD to placebo in NF1 children with ADHD-like symptoms. Children aged 7 to 12 years
were eligible when their IQ was between 80 and 120. The total follow-up was 9 weeks including 4 weeks for each
period and 1 week wash out. Fifty subjects (25 for each period) were required for testing the primary study hypothesis.
The main outcome was an improvement in scores on the simplified Conners’ Parent Rating Scale.
Results: Thirty-nine patients were included between April 2004 and December 2010. Twenty participants received MPD
and 19 placebo during the first period. They all completed the trial. MPD decreased the simplified Conners by 3.9
points (±1.1, p = 0. 0003).
Conclusions: This is the first randomised controlled trial showing the short-term benefit of MPD on simplified Conners
scores in NF1 children.
Trial registration: ClinicalTrials.gov NCT00169611.
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Neurofibromatosis type 1 (NF1), also known as von
Recklinghausen’s disease, is an autosomal dominant dis-
order with an estimated prevalence of about 1/3000 [1].
Caused by mutation in the NF1 gene, this condition is
characterised by multiple café-au lait spots, benign
neurofibromas and Lisch nodules [2].* Correspondence: laurence.lion-francois@chu-lyon.fr
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article, unless otherwise stated.The evolution of NF1 is unpredictable and highly vari-
able. It may be undetectable by the untrained eye, lead
to mild disfigurement or even life threatening conditions
[3]. The physical features of NF1 are well characterised,
facilitating the diagnosis after clinical examination.
The main complication of NF1 in childhood is cogni-
tive impairment, which affects quality of life and leads to
learning disabilities undermining academic achievement
in 30-70% of cases [4-6]. The cognitive disorders in NF1
include memory, switching attention coordination, lan-
guage, and behavioural disorders [7-9]. NF1 patients
have average intelligence quotient (IQ) scores, with aentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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retardation is 4-8%, which is slightly higher than in the
general population [4,10,11].
A high prevalence of ADHD-like characteristics is re-
ported in patients with NF1 [4,9,12-15]. The ADHD-like
behaviour in the NF1 population may be a major con-
tributor to academic underachievement in this popula-
tion [16]. Children with NF1 have difficulties with social
interactions, and present a high frequency of internalis-
ing features such as anxiety and depression [4]. It is
recognised that the cognitive, motor, and social prob-
lems are NF1-related disorders, rather than independent
comorbid conditions [17].
Medicines used to treat ADHD-like behaviours in NF1
patients have not been evaluated by randomized con-
trolled trials (RCTs). Methylphenidate seems to decrease
hyperactivity and increase the attention span and con-
centration by acting on dopaminergic and noradrenergic
neurotransmissions in the central nervous system [18].
Two systematic reviews suggest a favourable risk-benefit
profile for MPH [19,20]. Potential risks are headaches,
sleeping problems, tiredness, decreased appetite, psych-
otic symptoms and mood disorders.
It has been suggested that low doses (5 to 15 mg) of
methylphenidate (MPD) may improve Test of Variables
of Attention (TOVA) and Child Behaviour Checklist
(CBCL) scores after one-year of follow-up [14]. Even
though MPD has demonstrated its efficacy in reducing
ADHD behaviour in children [21], to our knowledge,
there have been no reported randomised controlled trials




The participants were 7 to 12 years of age with an IQ
between 80 and 120, measured using the Wechsler
Intelligence Scale for Children (WISC IIIR or WISC IV).
A child neurologist, a child psychiatrist and a psycholo-
gist enrolled children in two clinical sites, in Lyon and
Paris, if they met these inclusion criteria:
1. NF1 diagnosed using two or more of the following
National Institutes of Health (NIH) criteria [22]:
(1) six or more café au lait macules over 5 mm at
the greatest diameter in prepubertal children and
over 15 mm in postpubertal children, (2) two or
more neurofibromas of any type or one plexiform
neurofibroma, (3) freckling in the axillary or inguinal
regions, (4) two or more Lisch nodules, (5) optic
glioma, (6) a distinctive bone lesion such as
sphenoid dysplasia or thinning of long bone cortex
with or without pseudarthrosis, or (7) a first-degree
relative with NF1 as defined by the above criteria;2. School difficulties pointed out by parents or
teachers;
3. Attention difficulties as defined by anamnesis.
We had the following exclusion criteria:
1. 80 < IQ> 120 measured using the WISC III or WISC IV;
2. Depression;
3. Unwillingness to participate;
4. Patients with NF1 cerebral complications (chiasma
tumor, moya-moya, cerebral glioma) detected
using MRI;
5. Participation in another interventional study.
The NF1 Attention Study was a randomised, double-
blind, placebo-controlled, crossover trial. Total follow-
up lasted 9 weeks including 4 weeks for each period and
a 1-week wash out period.
The main outcome was the improvement of the sim-
plified Conners’ Parent Rating Scale [23] because it is
largely used in children and a French version was
available.
The short version comprises 10 questions and provides
evaluation of the key areas of inattention, hyperactivity/
impulsivity, learning problems, behavioural disorders,
anxiety, and peer relations. Specifically developed for de-
tecting hyperactivity, it allows quantifying the intensity
of hyperactivity and assessing its various dimensions:
hyperactivity, inattention and impulsivity. The score varies
from 0 to 30, scores >15 are prognostic of hyperactivity.
The secondary outcomes were the improvement of
scores on the Conners’ Teacher Rating Scale. The short
version comprises 10 questions provides evaluation of
the key areas of (behavioural disorders, hyperactivity/im-
pulsivity, immaturity and passivity). The interpretation
of scores is similar to Conner’s Parent Rating Scale.
The Children’s Depression Rating scale (CDRs-R) [24],
the Children’s Depression Inventory (CDI) [25], and the
State-trait Anxiety Inventory for Children (STAIc) [26]
were used in order to monitor anxiety and depression
symptoms of participants during the trial.
CDRs-R is a 17-item measure used to determine the
severity of depression in children 6–12 years of age. 14
items are based on parent, child and schoolteacher inter-
views, 3 items from the direct observation of children
(depression affects, language time, and hypoactivity).
Items are measured on 7 points or 5 points scale. The
CDRS is derived from the Hamilton Rating Scale for De-
pression (HAM-D); a score of 15 on the CDRS is
equivalent to a score of 0 on the HAM-D. A score ≥ 40
indicates depression but is not enough to confirm the
diagnosis. A score between 40 and 60 characterize light
or moderate and scores > 60 severe depression. Score <
30 are normal.
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determine the severity of depression in children for chil-
dren 7 to 17. It’s a psychological assessment that rates
the severity of symptoms related to depression and/or
dysthymic disorder in children and adolescents, is a 27-
item scale that is self-rated and symptom-oriented. Each
item is score from 0 to 2. The higher the score, the
higher the severity of depression. A score above 15 indi-
cates depression.
The STAIC consists of two 20-item scales that meas-
ure state and trait anxiety in children between the ages
of 8 and 14. The A-State scale examines the shorter-
term state anxiety that is commonly specific to situations
and the trait anxiety measures general anxiety. It
prompts the child to rate 20 statements from hardly ever
true (1point) to often true (3 points). Scores vary from
20 to 60. Score > 34 indicate anxiety.
Ethical approvals and consent
The study protocol was approved by the ethics commit-
tee « Comité de Protection des Personnes dans la
Recherche Biomédicale Sud Est II » (file number 2003–
042). The study was also registered on ClinicalTrials.gov
(NCT00169611). All subjects provided informed consent.
Sample size and power calculation
Based on a randomised controlled trial by Greenhill
et al. [23] and our clinical experience, increasing simpli-
fied Conners’ Parent Rating Scale scores by three points
was defined as a clinically relevant benefit. To achieve
this benefit with a 5% α risk (two-tailed), assuming a
within-subject standard deviation of 6.3, 50 subjects (25
for each period) were needed to test the primary study
hypothesis with 90% power.
Randomisation
Patients were enrolled at the Department of Paediatric
Neurology (Lyon and Paris Trousseau teaching hospi-
tals). Two physicians, a child neurologist, and a child
psychiatrist, asked for children’s assent and informed
consent from both parents. The identity of eligible pa-
tients was transmitted by the Department of Paediatric
Neurology to the Clinical Investigation Centre (CIC) of
Lyon and the MPD prescription was faxed to the central
pharmacy where a masked randomisation list according
to a computer generated randomization allowing con-
cealed allocation was available. Randomisation was per-
formed by a computer generated random number list
prepared by the department of biostatistics of the coord-
ination center with no clinical involvement in the trial.
The random list was created using SAS (version 8.2)
statistical software with a 1:1 allocation using block size
of 4.Patients received their treatment directly from the
central pharmacy. Neither patients nor investigators
knew which treatment was given.
The CIC and the Department of Biostatistics of Lyon
Teaching Hospitals, Lyon, France, conducted data man-
agement and statistical analyses. All data were recorder
in case report forms and entered by two independent
technicians blindly in a central secured database under
the responsibility of Clininfo. Site monitoring was car-
ried out by the CIC. A neurofibromatosis association
and the regional healthcare network for neurofibroma-
tosis informed potential eligible patients about the trial.
Intervention
MPD or matched placebo was started at a dose of
0.5 mg/kg/day and increased to 0.8 mg/kg/day if symp-
toms did not improve after a one-week check-up [13].
There was a one-week washout between the two treat-
ment periods to avoid a carry-over effect due to MPD’s
short half-life (2 hours) [24]. Treatment adherence was
measured by counting returned pills [25]. Six visits were
organized for the inclusion of eligible participants, ran-
domisation, dose-adjustment at week 1, end of first
period at week 4, debut of the second period at week 5,
the dose-adjustment at week 6, and end of study visit at
week 9. Efficacy measures and adverse events were col-
lected by the investigators.
The efficacy of MPD on ADHD disorders has been
proven using a minimum dose of 0.3 mg/kg/day. Ac-
cording to the guidelines, the patient should not be
given more than 2 or 3 doses of 1 mg/kg/day. Treatment
should begin with 5 mg, 2 times per day. The dose
should be gradually increased by 5-10 mg per week,
without exceeding the maximum dose of 60 mg per day
(source: leaflet from VIDAL).
Statistical analysis
The efficacy analyses adhered to the intention-to-treat
approach regardless of treatment status at the time of
analysis. To compare efficacy between MPD and pla-
cebo, we performed a two-factor analysis of variance
(ANOVA for repeated measures) on the 2 N measure-
ments with period and treatment factors (MPD versus
placebo). Interactions between patient characteristics
and treatment effect were also examined. Missing data
were replaced only when less than 50% of answers were
missing to compute a score. Imputation was performed
for each dimension (multidimensional scales) or directly
(one-dimensional scale) with the mean for completed
items [26]. The global score was then computed as the
sum of scores for each dimension (multidimensional
scales) or directly (one-dimensional scale).
The results presented in the tables are based on raw
data (score variations) but the p-values in the text were
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formed on normal scores from ranks computed with the
Van der Waerden method) [27]. Data from each patient
were used to estimate the treatment effect. Missing mea-
surements (7/78) were considered as missing by chance,
with the same mean as non-missing measurements.
None of the patients were excluded from the analysis.
Results
During the recruitment period, out of 664 children
screened with NF1 in our registry, 625 were disqualified.
This is because 564 did not satisfy inclusion criteria (443
under or over aged, others without attention difficulties,
etc.). The parents of 11 children did not give their consent.
Thirty-one were not enrolled for other reasons. The
reason for non-enrolment is unknown for 19 children
(Figure 1). The patient population is described in Table 1.
A total of 39 participants, 10 females and 29 males, aged
7.9-12.9 were included from April 2004 to December
2010. The mean age was 9.3 years ± 1.8. The baseline char-
acteristics of the patients did not differ significantly be-
tween the two groups, except that those in the MPD/
Placebo group had higher IQ scores (p = 0.03). SchoolAssessed for eligib
Lost to follow-up (n = 0)
Discontinued intervention ( n = 0) 
Allocated to intervention PL/MPD (n = 19)
•  Received intervention (n = 19)
•  Did not receive intervention (n = 0)
Analysed (n = 71/78 obs


























Figure 1 Participants flow diagram.difficulties in 33% (13/39) of the participants lead to edu-
cational consequences. One was in a special class and 12
repeated a grade. Scores on the Conners’ Global Index-
Parent (short version) did not differ statistically between
groups at baseline (p = 0.37) and neither did the other
Conners’ scores (p ≥ 0.12). Based on the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV), 18 participants presented ADHD symptoms,
12 only had attention deficit and 2 only had hyperactivity.
Seven patients do not present attention deficit or hyper-
activity symptoms but remain eligible because they pre-
sented school difficulties and attention deficit based on
the anamnesis.
The 39 patients completed the entire 9 weeks study
evaluation. Twenty participants received MPD and 19 pla-
cebo during the first period. We did not detect any carry-
over effect between the two periods (p = 0.41). The flow
diagram of patient recruitment and follow-up is presented
in Figure 1.
Simplified Conners’ Parent Rating Scale scores de-
creased by 3.9 points (±1.1, p = 0. 0003). Results on pri-
mary and secondary outcomes are presented in Table 2.
In the MPD group, the baseline score (mean ± SD) ofility (n = 664) 
Excluded (n = 625)
•  Not meeting inclusion criteria (n = 564)
•  Refused to participate (n = 11)
• Other reasons (n = 50)
Lost to follow-up (n = 0)
Discontinued intervention ( n = 0)
ervations)
sis ( n = 7 observations) : 
 available
 = 39)
Allocated to intervention MPD/PL (n = 20)
•  Received intervention (n = 20)
•  Did not receive intervention (n = 0)
Table 1 Demographics and baseline characteristics of the
participants
MPD/Placebo Placebo/MPD
(n = 20) (n = 19)
Age (y)
Mean* 9.60 +/−2.02 8.98 +/−1.63
Range 7.09-12.99 7.21-11.81
Gender
Male 16 (80.0%) 13 (68.4%)
Female 4 (20.0%) 6 (31.6%)
Weight (kg)* 29.34 (5.91) 29.04 (6.14)
Height (cm)* 132.50 (10.09) 133.63 (9.15)**
School backwardness◊ 6 (30.0%) 7 (36.8%)
IQ* 102.0 (12.5)‡ 94.6 (11.2)†
Conners’ global index-Parents* 66.2 (13.9)‡ 69.8 (16.1)†
Conners’ global index-Teacher* 55.9 (8.4)¥ 59.8 (9.0) ¥
Conners’ global index-Short
version-Parents*
15.2 (5.2) 13.7 (6.4)
Conners’ global index-Short
version-Teacher*
8.1 (4.7)¤ 11.9 (6.1)**
CDRS-R* 29.9 (7.8) 27.6 (7.4)
CDI* 11.0 (6.5) 10.0 (4.6)
STAI-C 1* 12.9 (7.4) 10.9 (6.5)
STAI-C 2* 15.9 (9.1) 13.3 (7.5)
DSM IV THADA [28]
Inattention* 6.8 (1.5) 6.9 (2.0)
Hyperactivity/Impulsivity* 5.3 (2.0) 5.8 (3.0)
Hyperactivity* 3.0 (1.6) 3.9 (2.1)
Impulsivity* 2.3 (0.7) 1.9 (1.2)
*Mean +/− SD.







Table 2 Efficacy of methylphenidate on the simplified
Conners’ rating scale and other secondary endpoints




−5.7 (−7.3, −4.1) -1.8 (−3.4, −0.1) -3.9 (−6.1, −1.7)
Teacher’s version −3.5 (−5.8, −1.2) -1.6 (−3.8, 0.6) -1.9 (−5.0, 1.1)*
CDRs −2.9 (−5.0, −0.9) -1.9 (−4.0, 0.2) -1.1 (−4.0, 1,8)
CDI −2.1 (−3.9, −0.4) -1.9 (−3.7, −0.1) -0.2 (−2.7, 2.3)
STAIc-state −3.2 (−5.1, −1.2) -1.9 (−3.8, 0.1) -1.3 (−4.0, 1.4)
STAIc-trait −3.1 (−5.2, −1.0) -2.7 (−4.8, −0.6) -0.3 (−3.3, 2.6)
*NS, 50% of data were missing.
Mean variation (95% confidence limits).
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week 4. The baseline and week 4 mean scores in the pla-
cebo group were 12.7 ± 6.9 and 10.8 ± 6.9. (Figure 2).
The effect of MDP on simplified Conners’ Teacher
Rating Scale scores cannot be interpreted because half of
the data were missing. MDP had no effect on depression
scores (CDRs and CDI) or on anxiety scores (STAIC-
state and STAIC-trait).
Non-adherence to methylphenidate with no apparent
reason was reported for two children. Mean compliance
was 75.30% (SD ± 13.56), ranging from 26.42 to 100%;
with a median of 77.40% and an upper quartile of 81.17%.
The mean dose of MPD prescribed was 16.3 mg/day.
Compliance was not evaluated for 11 patients because ofmissing data (7 in the sequence group MPD/Placebo and
4 in the sequence group Placebo/MPD). When available,
compliance was not statistically different between se-
quence groups (p = 0.66).
Adverse events are reported in Table 3. One serious
adverse event was reported in a patient, who had gastro-
intestinal disorders while taking MPD. The investigator
found that this event was not related to the study drug.
Discussion
In our daily clinical practice visiting patients referred for
NF1 present a high prevalence of ADHD-like symptoms
and academic underachievement. No evidence-based
guideline on how to treat these patients is currently avail-
able. Our study aimed to answer the question whether our
everyday patients with NF1 having ADHD-like character-
istics based on the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV), could poten-
tially benefit from methylphenidate without being harmed
by adverse events such as depression or anxiety disorders.
In our study Conners’ Parent Rating Scale scores de-
creased by 3.9 points by MPD, suggesting a clinically rele-
vant benefit. Our results are very close to those observed
in children with ADHD reported by Greenhill et al. [23].
Because of the high number of missing questionnaires for
our secondary outcome, we were not able to show a sig-
nificant reduction in symptoms, based on results from the
teacher version of the 10-item Conners’ Global Index.
After the end of the study, 37 participants continued
to take MPD or switched from placebo to MPD. This
group had normal IQ. Scores on the CDRS, the CDI,
and the STAIC [29] did not increase in NF1 patients be-
fore treatment or during the four weeks into the study.
MPD did not seem to have an impact on depression and
anxiety during our study.
Stimulants are the main drugs used to treat ADHD.
Defining the target population [30] and ensuring the
safety of stimulants are sources of concern and regularly
relayed by the media [31]. A database evaluation of the
Figure 2 Evolution of the principal outcome, Conner’s global index short version by treatment group and for each period.
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1995, but it is not clear if this practice is appropriate
[30]. The use of MPD has been limited to patients with
neurological disorders because of its side effects such as
motor tics, sleep disorders, headaches, decreased appe-
tite, stomach pain, nausea, irritability, seizures [32], and
growth suppression [33]. However, it is not certain that
MPD is responsible for these adverse events. For in-
stance, the tic rate reported by Schachar et al. was simi-
lar in children taking placebo and those treated with
MPD [34]. In a recent long-term follow-up study, loss of
appetite was the most common adverse effect of MPD
[25]. Administration of MPD during or after meals mayTable 3 Adverse events reported in each group
Placebo (%) MPD (%) Total
Insomnia, Anxiety/Nervousness 2 (16,67) 11 (37,93) 13
Headache 3 (25,00) 3 (10,34) 6
Anorexia/Decreased appetite 0 (0,00) 6 (20,69) 6
Abdominal pain 2 (16,67) 2 (6,90) 4
Abnormal loss of weight 1 (8,33) 1 (3,45) 2
Vomiting/Nausea 0 (0,00) 2 (6,90) 2
Other* 4 (33,33) 4 (13,79) 8
Total 12 29 41
*Tonsillitis, dysphemia, hot flush, enuresis, asthenia, attention deficit, rash.minimize the influence of anorexia. The correlation be-
tween growth suppression and treatment has not yet
been established and it is not clear whether drug holi-
days are necessary, even though they are recommended
in France [35]. Drug holidays during summer months
have been proposed as “catch up” growth periods [33].
Lastly, a recent study showed that current users of
ADHD drugs did not have an increased risk of develop-
ing serious cardiovascular events [36].
There are several limitations to this study. We used
the French version of the Conners’ Parent Rating Scale
because it was the only scale available in French when
we started our study. Few questionnaires were received
for the teacher version, but their results show also a
beneficial trend during the MPD period (−1.9, p = 0.22).
Even though another NF1 reference centre in Paris
helped recruiting patients, we did not reach our target
sample size of 50 patients. The two-year recruitment
period planned for our study was not long enough
mainly because, MPD could not be prescribed during
school holidays because dose adaptation requires close
patient monitoring, potential hyperactivity drug-related
deaths made parents suspicious of its safety [31] and re-
luctant to participate, and finally, exclusion criteria were
more common than anticipated. We asked an independ-
ent data monitoring committee (DMC) comprising a
clinical pharmacologist and a biostatistician to advise us
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the trial earlier. The DMC did not un-blind the data and
suggested extending the recruitment period by one year
to include three or four more patients. This would mean
10% more participants and would have potentially in-
creased the power of the study. After these measures
were implemented (March 2005), we were able to in-
clude 39 of the 50 participants we had originally hoped
for. After 54 months extension, the study was stopped
because the available pool of patients was already
screened for the trial and the pool of newly diagnosed
patients would not allow us to terminate the study
within an acceptable period of time. However, our final
results suggest that the efficacy of MPD was greater
than expected. Finally, the duration of the treatment
by MPD was only four weeks and the long-term bene-
fit should be assessed adequately.
Conclusion
MPD showed a short-term benefit on the Conners’ Par-
ent Rating Scale in NF1 children with school difficulties
and attention deficit.
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